EXEL : Summary for Exelixis, Inc. - Yahoo Finance

U.S. Markets closed

Exelixis, Inc. (EXEL)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.53+0.24 (+1.31%)
At close: 4:00PM EST
People also watch
ARRYARIACLDXIMGNSGEN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close18.29
Open18.27
Bid18.29 x 200
Ask18.73 x 100
Day's Range17.86 - 18.55
52 Week Range3.55 - 19.30
Volume3,197,132
Avg. Volume5,875,053
Market Cap5.31B
Beta2.38
PE Ratio (TTM)-28.16
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Better Buy: Exelixis, Inc. vs. Novartis
    Motley Foolyesterday

    Better Buy: Exelixis, Inc. vs. Novartis

    Let's see how one of the best biotech stocks of 2016 stacks up to the pharmaceutical giant from Switzerland.

  • Exelixis, Inc. – Value Analysis (NASDAQ:EXEL) : January 11, 2017
    Capital Cube13 days ago

    Exelixis, Inc. – Value Analysis (NASDAQ:EXEL) : January 11, 2017

    Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Exelixis, Inc. a score of 28. Our analysis is based on comparing Exelixis, Inc. with the following peers – Sanofi Sponsored ADR, Merck & Co., Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc Sponsored ADR, Amgen Inc., Johnson & Johnson, ArQule, Inc., Pfizer Inc., AVEO Pharmaceuticals, Inc. and Curis, ... Read more (Read more...)

  • After ARIAD's Acquisition, These 3 Cancer Drug Stocks Could Be Next
    Motley Fool14 days ago

    After ARIAD's Acquisition, These 3 Cancer Drug Stocks Could Be Next

    Following Takeda's multibillion-dollar acquisition of cancer drugmaker Ariad Pharmaceuticals, Array Biopharma, Seattle Genetics, and Exelixis could be the next to be bought.